Population Council

Knowledge Commons

2015

Strengthening the role of patent medicine vendors in the provision
of injectable contraception in Nigeria
Population Council
The Evidence Project

Follow this and additional works at: https://knowledgecommons.popcouncil.org/departments_sbsr-rh
Part of the Community Health and Preventive Medicine Commons, Demography, Population, and
Ecology Commons, Family, Life Course, and Society Commons, International Public Health Commons, and
the Women's Health Commons

How does access to this work benefit you? Let us know!
Recommended Citation
"Strengthening the role of patent medicine vendors in the provision of injectable contraception in Nigeria,"
Activity brief. Washington, DC: Population Council, The Evidence Project, 2015.

This Brief is brought to you for free and open access by the Population Council.

Strengthening the Role of
Patent Medicine Vendors in the Provision of
Injectable Contraception in Nigeria
Photo by: Bill Brieger/JHPIEGO

AC T I V IT Y BR I E F

Nigeria is Africa’s most
populous nation, with a
population of approximately
140 million people. Modern
contraceptive services are
underutilized in Nigeria which
has a modern contraceptive
prevalence rate (CPR) of 11
percent. The country’s low
CPR highlights the need for
innovative programs to increase
women’s access to contraceptive
services.

In Nigeria, the majority of contraceptive services are offered in private
settings, including Patent Medicine (PM) shops. PM shops are informal businesses owned by Patent Medicine Vendors (PMVs) licensed
to sell patent or propriety drugs. PMVs sell a range of contraceptive
commodities including male and female condoms, emergency contraceptives, pills, and intrauterine devices.
Injectable contraception is the most popular modern method in
Nigeria, accounting for 30 percent of current modern contraceptive
users. Current regulations do not permit PMVs to sell or administer
injectable contraceptives because PMVs do not currently receive
formal training. Instead, they can only refer clients to health facilities
for injection sale and administration. Nevertheless, some PMVs are
selling and administering injectable methods in response to high
demand for them.
Given this situation, now is an opportune time to generate evidence
that can drive policy action to formally train and engage PMVs in the
provision of safe injectable contraceptive services as a key strategy in
increasing women’s access to contraceptive methods.

STUDY OBJECTIVES
The Evidence Project, in collaboration with the Federal Ministry of
Health (FMOH), is conducting implementation research to:
1. Demonstrate the feasibility of PMVs administering all available
forms of injectable contraception, including Depo Provera (DMPA)
and Sayana® Press.
2. Understand women’s experiences using DMPA or Sayana® Press,
including the quality of care they receive when accessing injectable contraceptive services from PMVs.
The FMOH also asked the Evidence Project to develop and coordinate
training of PMVs so that they have the necessary skills and information to sell, counsel, and refer for all contraceptive methods, as
well as administer all injectable contraceptives, including DMPA and
Sayana® Press.
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The study is taking place in two states: Oyo in the southwest and
Nassarawa in north central Nigeria. In each state, four Local Government Areas (LGAs) will be selected as the study sites (two urban and
two rural) for a total of eight LGAs.

Injectable Contraceptive Methods
There are two types of injectable hormonal contraceptives: those that are injected intramuscularly, like DMPA,
and those that are injected subcutaneously, like Sayana®
Press. In Nigeria, intramuscular injections were the only
available option for women wishing to use injectable contraception until 2014 when Sayana® Press was introduced
as a second safe and efficacious option. Sayana® Press
comes as a single dose in a prefilled, sterile syringe, and
is administered once every three months. It is packaged in
the Uniject injection system with an autodisposable device
that eliminates the need to prepare a needle and syringe.
Because the type of injection is subcutaneous, the needle
is smaller and thus less painful.

THE PILOT INTERVENTION
PMVs who volunteer to participate in the study will take
part in a five-day, participatory training on providing information and counseling to clients on all family planning
methods and on administering injectable contraceptives.
The training will cover the differences between intramuscular and subcutaneous injectable contraceptives (see
Box); their safe storage and administration; and counseling
women on side effects, when to return for the follow-up
injection, and what to do if an adverse event occurs.
The research team will establish or strengthen relationships with a number of stakeholders, including the National
Association of Patent and Proprietary Medicine Dealers
(NAPMED) whose members will help recruit PMVs for the
study, review training materials and participate in the
training, and interpret the study’s findings. The team will
also work with local government health facilities in the eight
LGAs to ensure the acceptance of referrals by PMVs. Additionally, FMOH and LGA health staff will be involved in the
planning, implementation, and training of PMVs. To reduce
the likelihood of stock-outs of DMPA and Sayana® Press,
Society for Family Health (SFH) and DKT will be actively
involved in this study. SFH and DKT are the respective organizations responsible for distributing DMPA and Sayana®
Press in the private sector in Nigeria.

HOW THE DATA ARE BEING COLLECTED
Pre- and post-PMV training surveys
The PMVs will complete a survey pre- and post-training to
ascertain changes in knowledge and practices related to
injectable contraceptives. Additionally, follow-up surveys
will be administered at three, six, and nine months post
training to assess the PMV’s practices, knowledge and
skills over time.

Monthly monitoring/supervision of PMVs
Teams of study investigators and Ministry of Health
officials will monitor activities of trained PMVs through
monthly follow-up meetings to identify and resolve
implementation issues. The monitoring visits will track
progress, challenges, and successes of implementation
as well as gather information on clients’ experience of
adverse events.

Client exit interviews and surveys
To obtain female clients’ perspectives, the researchers
will conduct exit interviews at PM shops of trained PMVs.
They will also recruit and follow over time a cohort of
DMPA and Sayana® Press users receiving services from
trained PMVs, enabling the assessment of continuation
rates of injectable contraceptive methods.

FOSTERING RESEARCH UTILIZATION
The research team will engage key decision makers, such
as the FMOH and state and LGA health officials, from the
beginning of the study; utilize technical working groups to
discuss emerging findings and lessons; and identify champions to promote the study findings to key stakeholders,
such as health officials, NAPMED, PMVs, Pharmacy Council
of Nigeria, donors, NGOs, etc. A national dissemination
meeting will be held in Abuja with the key stakeholders to
review and interpret the results and identify how they can
be translated into policy. State level meetings also will be
held to share implementation successes and challenges to
PMV delivery of injectable contraceptive services.

The Evidence Project is led by the Population Council
in partnership with INDEPTH Network, International
Planned Parenthood Federation, Management
Sciences for Health, PATH, Population Reference
Bureau, and a University Research Network. Other
partners are FHI360, Meridian Group International,
Inc., and What Works Association.
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